BTTX

Better Therapeutics, Inc. [BTTX] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?
RSI : 000

BTTX Stock Summary

Top BTTX Correlated Resources

BTTX


Top 10 Correlated ETFs

BTTX


Top 10 Correlated Stocks

BTTX


In the News

10:34 11 Dec 2023 BTTX

Better Therapeutics, Inc. (BTTX) Q2 2023 Earnings Call Transcript

Better Therapeutics, Inc. (NASDAQ:BTTX ) Q2 2023 Earnings Conference Call August 9, 2023 4:30 PM ET Company Participants Mark Heinen - Chief Financial Officer Frank Karbe - President and CEO Diane Gomez - Chief Commercial Officer Mark Berman - Chief Medical Officer Conference Call Participants Thomas Flaten - Lake Street Capital Markets Keay Nakae - Chardan Rahul Rakhit - LifeSci Capital Operator Good day and thank you for standing by, and welcome to the Better Therapeutics' Second Quarter 2023 Update Call. At this time all participants are in a listen-only mode.

05:30 11 Dec 2023 BTTX

Better Therapeutics to Release Second Quarter 2023 Financial Results and Provide Business Update on August 09, 2023

SAN FRANCISCO--(BUSINESS WIRE)---- $BTTX #digitalhealth--Better Therapeutics, Inc. (NASDAQ: BTTX), a pioneer in developing prescription digital therapeutics to treat cardiometabolic diseases, today announced it will release its second quarter 2023 financial results after the market closes on Wednesday, August 09, 2023. Management will host a conference call and webcast to provide a business update at 4:30 p.m. ET / 1:30 p.m. PT on Wednesday, August 09, 2023. To access the conference call, please register at: https://re.

08:57 11 Dec 2023 BTTX

Why Is Better Therapeutics (BTTX) Stock Up 39% Today?

Better Therapeutics (NASDAQ: BTTX ) stock is taking off on Tuesday as investors react to approval from the FDA for a Type 2 diabetes treatment. This covers AspyreRx, which is a prescription-only digital therapeutic treatment for patients 18 and older with Type 2 diabetes.

04:13 11 Dec 2023 BTTX

Better Therapeutics, Inc. (BTTX) Q1 2023 Earnings Call Transcript

Better Therapeutics, Inc. (NASDAQ:BTTX ) Q1 2023 Earnings Conference Call May 11, 2023 8:30 AM ET Company Participants Mark Heinen - CFO Frank Karbe - President and CEO Diane Gomez - Chief Commercial Officer Mark Berman - Chief Medical Officer Conference Call Participants Thomas Flaten - Lake Street Capital Markets Lucas Romanski - TD Cowen Keay Nakae - Chardan Keay Rahul Rakhit - LifeSci Capital Operator Good morning and thank you for standing by, and welcome to the Better Therapeutics' First Quarter 2023 Conference Call. At this time all participants are in a listen-only mode.

01:42 11 Dec 2023 BTTX

Better Therapeutics, Inc. (BTTX) Moves to Buy: Rationale Behind the Upgrade

Better Therapeutics, Inc. (BTTX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

10:27 11 Dec 2023 BTTX

Better Therapeutics, Inc. (BTTX) Q3 2022 - Earnings Call Transcript

Better Therapeutics, Inc. (NASDAQ:BTTX ) Q3 2022 Earnings Conference Call November 14, 2022 4:30 PM ET Company Participants Mark Heinen - Chief Financial Officer Frank Karbe - President and Chief Executive Officer Mark Berman - Chief Medical Officer Diane Gómez-Thinnes - Chief Commercial Officer Conference Call Participants Thomas Flaten - Lake Street Capital Markets Rahul Rakhit - LifeSci Capital Keay Nakae - Chardan Operator Good afternoon, and welcome to the Better Therapeutics Third Quarter 2022 Financial Results and Business Update Conference Call. At this time, all participants are in a listen-only mode.

06:34 11 Dec 2023 BTTX

Better Therapeutics, Inc. (BTTX) CEO Frank Karbe on Q2 2022 Results - Earnings Call Transcript

Better Therapeutics, Inc. (NASDAQ:BTTX ) Q2 2022 Earnings Conference Call August 11, 2022 8:30 AM ET Company Participants Mark Heinen – Chief Financial Officer Frank Karbe – President and Chief Executive Officer Mark Berman – Chief Medical Officer Conference Call Participants Thomas Flaten – Lake Street Capital Rahul Rakhit – LifeSci Capital Keay Nakae – Chardan Operator Good morning, and welcome to the Better Therapeutics Second Quarter 2022 Financial Results and Business Update Conference Call. At this time, all participants are in a listen-only mode.

11:10 11 Dec 2023 BTTX

Why Is Better Therapeutics (BTTX) Stock Up 27% Today?

Source: Minerva Studio / Shutterstock.com Better Therapeutics (NASDAQ: BTTX ) stock is rocketing higher on Thursday as investors react to results from a Phase 2 clinical trial. This Phase 2 study saw Better Therapeutics using BT-001 to treat type 2 diabetes.

07:30 11 Dec 2023 BTTX

Better Therapeutics to Host Conference Call to Review Results from Pivotal Clinical Trial of BT-001 for Type 2 Diabetes

SAN FRANCISCO--(BUSINESS WIRE)--Better Therapeutics, Inc. (NASDAQ: BTTX), a prescription digital therapeutics (PDT) company developing nutritional cognitive behavioral therapy (nCBT) to address the root causes of cardiometabolic diseases, today announced it will host a conference call and webcast on Thursday, July 28, 2022, at 8:30 a.m. ET to review the results from the pivotal clinical trial of BT-001 after 180 days of treatment for type 2 diabetes. Members of the Better Therapeutics managemen

07:45 11 Dec 2023 BTTX

3 Penny Stocks That Have Huge Catalysts Ahead

While you don't want to play with money you can't afford to lose, these penny stocks might bring home the goods for the bold. The post 3 Penny Stocks That Have Huge Catalysts Ahead appeared first on InvestorPlace.

BTTX Financial details

Company Rating
Neutral
Market Cap
10.98M
Income
-31.57M
Revenue
0
Book val./share
-0.26
Cash/share
0.17
Dividend
-
Dividend %
-
Employees
54
Optionable
No
Shortable
Yes
Earnings
09 Nov 2023
P/E
-0.28
Forward P/E
-0.41
PEG
0.04
P/S
-
P/B
-0.9
P/C
1.36
P/FCF
-0.4
Quick Ratio
0.51
Current Ratio
0.57
Debt / Equity
-1.44
LT Debt / Equity
-0.78
-
-
EPS (TTM)
-1.15
EPS next Y
-0.56
EPS next Q
-0.19
EPS this Y
-45.66%
EPS next Y
-51.3%
EPS next 5Y
-6.09%
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
-37.5%
-
-
-
-
SMA20
40%
SMA50
-43.24%
SMA100
-75.86%
Inst Own
6.07%
Inst Trans
1.34%
ROA
-294%
ROE
401%
ROC
13.36%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
47.4M
Shs Float
23.31M
-
-
-
-
Target Price
17
52W Range
0.137-1.61
52W High
-
52W Low
-
RSI
57.82
Rel Volume
0.24
Avg Volume
2M
Volume
474.42K
Perf Week
21.89%
Perf Month
21.45%
Perf Quarter
-74.96%
Perf Half Y
-69.92%
-
-
-
-
Beta
2.472
-
-
Volatility
0.02%, 0.03%
Prev Close
-1.49%
Price
0.2316
Change
0.52%

BTTX Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2022-12-31

Metric History 2019-12-312020-12-312021-12-31 2022-12-31
2.02K2.02K2.02K2.02K
Revenue per share
0000
Net income per share
-0.25-0.27-3.11-1.69
Operating cash flow per share
-0.26-0.24-2.37-1.23
Free cash flow per share
-0.38-0.34-2.46-1.28
Cash per share
0.030.013.120.67
Book value per share
-0.03-0.292.83-0.04
Tangible book value per share
-0.16-0.522.44-0.2
Share holders equity per share
-0.03-0.292.83-0.04
Interest debt per share
0.210.030.750.69
Market cap
236M236M60.37M26.15M
Enterprise value
240.24M236.51M29.31M25.29M
P/E ratio
-40.72-36.95-1.5-0.66
Price to sales ratio
13.11K29.5K00
POCF ratio
-37.96-40.87-1.96-0.9
PFCF ratio
-26.36-29.21-1.89-0.87
P/B Ratio
-390.08-34.921.64-29.09
PTB ratio
-390.08-34.921.64-29.09
EV to sales
13.35K29.56K00
Enterprise value over EBITDA
-42.14-37.85-0.96-0.66
EV to operating cash flow
-38.64-40.96-0.95-0.87
EV to free cash flow
-26.83-29.28-0.92-0.84
Earnings yield
-0.02-0.03-0.67-1.52
Free cash flow yield
-0.04-0.03-0.53-1.15
Debt to equity
-8.26-0.090.26-16.55
Debt to assets
1.020.10.190.65
Net debt to EBITDA
-0.74-0.081.020.02
Current ratio
2.030.769.561.37
Interest coverage
-524.82-63.23-165.19-25.66
Income quality
1.070.90.760.73
Dividend Yield
0000
Payout ratio
0000
Sales general and administrative to revenue
122.06306.8800
Research and developement to revenue
127.22372.2500
Intangibles to total assets
0.670.870.10.17
Capex to operating cash flow
0.440.40.030.04
Capex to revenue
-152-288.1300
Capex to depreciation
-38-30.73-0.66-0.43
Stock based compensation to revenue
4.6729.1300
Graham number
0.381.3214.061.2
ROIC
-1.321.06-0.66-2.74
Return on tangible assets
-3.59-7.68-0.88-2.09
Graham Net
-0.2-0.552.03-0.34
Working capital
501K-150K40.52M4.95M
Tangible asset value
-3.87M-12.31M31.64M-4.79M
Net current asset value
-4.5M-12.68M31.01M-5.4M
Invested capital
-8.26-0.090.26-16.55
Average receivables
0000
Average payables
0424.5K1.02M2.28M
Average inventory
0000
Days sales outstanding
0000
Days payables outstanding
136.16275.0900
Days of inventory on hand
0000
Receivables turnover
0000
Payables turnover
2.681.3300
Inventory turnover
0000
ROE
9.580.95-1.144.23
Capex per share
-0.12-0.1-0.08-0.05

Quarterly Fundamentals Overview

Last date of statement is 2023-09-30 for Q3

Metric History 2022-09-302022-12-312023-03-312023-06-30 2023-09-30
2.02K2.02K2.02K2.02K2.02K
Revenue per share
00000
Net income per share
-0.48-0.37-0.39-0.24-0.15
Operating cash flow per share
-0.3-0.27-0.37-0.16-0.15
Free cash flow per share
-0.31-0.28-0.39-0.18-0.15
Cash per share
0.940.660.250.20.17
Book value per share
0.31-0.04-0.41-0.35-0.26
Tangible book value per share
0.13-0.2-0.57-0.46-0.33
Share holders equity per share
0.31-0.04-0.41-0.35-0.26
Interest debt per share
0.640.650.630.470.36
Market cap
41.7M26.36M16.68M33.71M14.09M
Enterprise value
34.18M25.5M25.15M41.73M21.8M
P/E ratio
-0.91-0.75-0.45-1.11-0.6
Price to sales ratio
00000
POCF ratio
-5.94-4.16-1.91-6.63-2.37
PFCF ratio
-5.65-3.94-1.81-6.03-2.37
P/B Ratio
5.75-29.32-1.7-3.12-1.42
PTB ratio
5.75-29.32-1.7-3.12-1.42
EV to sales
00000
Enterprise value over EBITDA
-3.32-3.06-2.82-6.7-4.08
EV to operating cash flow
-4.87-4.02-2.89-8.2-3.67
EV to free cash flow
-4.63-3.81-2.72-7.46-3.66
Earnings yield
-0.27-0.33-0.56-0.23-0.42
Free cash flow yield
-0.18-0.25-0.55-0.17-0.42
Debt to equity
2.04-16.55-1.48-1.32-1.44
Debt to assets
0.520.651.141.221.33
Net debt to EBITDA
0.730.1-0.95-1.29-1.44
Current ratio
2.521.370.620.530.57
Interest coverage
-27.08-18.96-20.71-12.4810.31
Income quality
0.620.720.930.671.01
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
00000
Research and developement to revenue
00000
Intangibles to total assets
0.150.170.290.310.26
Capex to operating cash flow
0.050.060.060.10
Capex to revenue
00000
Capex to depreciation
-0.52-0.5-0.69-0.63-0.01
Stock based compensation to revenue
00000
Graham number
1.820.561.911.370.94
ROIC
-0.5-0.6-1.9-2.05-1.22
Return on tangible assets
-0.47-0.46-1.03-0.95-0.74
Graham Net
0.06-0.34-0.7-0.52-0.37
Working capital
14.18M4.95M-5.2M-6.45M-5.59M
Tangible asset value
3.13M-4.79M-13.59M-14.37M-12.73M
Net current asset value
2.52M-5.4M-14.2M-14.97M-13.31M
Invested capital
2.04-16.55-1.48-1.32-1.44
Average receivables
00000
Average payables
1.17M2.15M2.77M2.75M2.65M
Average inventory
00000
Days sales outstanding
00000
Days payables outstanding
00000
Days of inventory on hand
00000
Receivables turnover
00000
Payables turnover
00000
Inventory turnover
00000
ROE
-1.579.750.950.70.59
Capex per share
-0.02-0.02-0.02-0.020

BTTX Frequently Asked Questions

What is Better Therapeutics, Inc. stock symbol ?

Better Therapeutics, Inc. is a US stock , located in San francisco of Ca and trading under the symbol BTTX

What is Better Therapeutics, Inc. stock quote today ?

Better Therapeutics, Inc. stock price is $0.2316 today.

Is Better Therapeutics, Inc. stock public?

Yes, Better Therapeutics, Inc. is a publicly traded company.

Something similar

Top by Market Cap
Top Correlated Stocks
Similar Market Cap